发明名称 Ribavirin-pegylated interferon alfa induction HCV combination therapy
摘要 There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a therapeutically effective inducing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.
申请公布号 US6824768(B2) 申请公布日期 2004.11.30
申请号 US19990464426 申请日期 1999.12.16
申请人 SCHERING CORPORATION 发明人 STALGIS CARLOS O.;ALBRECHT JANICE K.;GLUE PAUL W.
分类号 A61K31/7056;A61K38/21;(IPC1-7):A61K38/21;A61K39/00;A61K39/29;A61K31/70;C07K38/21 主分类号 A61K31/7056
代理机构 代理人
主权项
地址